AstraZeneca PLC

DUBLIN, Sept. 29, 2023 /PRNewswire/ -- ResearchAndMarkets.com proudly announces the addition of the "Next-Gen Digital Pathology Conference" to its extensive list of offerings, set to take place on 19th-20th October 2023. As digital pathology emerges as a significant technology in recent years, this conference emerges as a pivotal meeting ground for experts and enthusiasts alike, emphasizing education, tissue-based research, medication development, and human pathology practice. Conference Highlights: The two-day event promises insightful discussions into slide-free imaging, enterprise-wide solutions, machine learning, and AI algorithms that are changing the face of diagnoses and treatments. Attendees can look forward to informative sessions on topics like computational pathology & cloud computing, digital pathology's role in clinical decision making, and the latest advancements in imaging technologies. Key industry figures will lead enlightening presentations, including Dr. Aneesh Acharya from Molecular Instruments, Inc and Carl Barrett from AstraZeneca. Other highlights include innovative research displays, sessions on AI's role in drug discovery, and workshops centered on ensuring quality in digital pathology. Agenda Sneak Peek: Day 1 (19th Oct) focuses on the strategic aspects, challenges, and scopes of digital pathology with keynotes on the future developments and implications of the technology. Day 2 (20th Oct) delves into computational pathology, AI's influence on imaging and digital image analysis, and an in-depth look at how digital pathology and AI are revolutionizing pathology labs. Prominent Speakers: Anil Parwani, Director of Pathology Informatics, The Ohio State University. Sunil Singhal, Chief of Digital Pathology Transformation, Baylor College of Medicine. Shoh Asano, Principal Scientist Microscopy and Image Analysis, Pfizer. Carl Barrett, VP, Translational Science, Oncology, AstraZeneca. And many other esteemed professionals. Who Should Join? Pharma professionals including CEOs, COOs, senior scientists, research scientists, and managers. Academic leaders like professors, researchers, and deans from top universities. Healthcare professionals from hospitals and their pathology, diagnostics, and hematology departments. Laboratories' pathologists, managers, directors, and technicians. Why Attend? Engage in expert-led discussions, get familiarized with the latest tech implementations in the industry, and discover sustainable solutions through workshops and interactive panels. Moreover, the Young Researchers Forum presents a unique chance to witness the future pioneers of the industry. Agenda: Day 1 Thu, 19-Oct-2023 Keynote Presentation - "Benefits, Future Developments, and Implications of Digital Pathology" DIGITAL PATHOLOGY - STRATEGY, CHALLENGES AND SCOPE The current landscape of digital pathology HCRT Imaging: Modern tools built for mission-critical workflows Dr. Aneesh Acharya, Vice President of Commercial, Molecular Instruments, Inc EU landscape with respect to GDP and how does it impact Solution Provider Presentation What is digital pathology in artificial intelligence research space? Advancing preclinical and diagnostic pathology with AI ROLE OF PHARMA IN DIGITAL PATHOLOGY Use of digital pathology in artificial intelligence for prediction and for better patient identification for appropriate treatment Digital Pathology & AI in Drug Discovery Digital pathology in toxicology pathology Analyzing the Business Case for Digital Pathology Closing Remarks from the Chairperson Day 2 Fri, 20-Oct-2023 Keynote Presentation - "A practical overview of the Use of digital pathology and artificial intelligence by pathology labs" COMPUTATIONAL PATHOLOGY Understanding and Integrating Computational Pathology Computational Pathology: The next revolution in cancer diagnosis Carl Barrett, VP, Translational Science, Oncology, AstraZeneca Predictive models based on machine learning and AI Cloud Computing/Storage Solutions - AI FOR IMAGING AND DIGITAL IMAGE ANALYSIS Advantages of a Large-Scale Clinical Workflow Together with a Pharma Research Data Repository Sunil Singhal, Chief of Digital Pathology Transformation, Baylor College of Medicine Identification and validation of a pro-fibrogenic macrophage population using cyclic immunofluorescence imaging Shoh Asano, Principal Scientist Microscopy and Image Analysis, Pfizer Overcoming Challenges in Image Analysis Research and applications of artificial intelligence in quantitative image analysis Pattern recognition and image analysis- manually and fully automated Closing Remarks from the Chairperson For more information about this conference visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Mid-Autumn Festival又是团圆之日，E药经理人在此祝福全体医药人阖家欢乐！中秋、国庆双节来临，8天长假正是出游和返乡的好时光。各位小伙伴们，你是否已经踏上了出行或归家之路？如果你正在打发漫长的旅途，不如先随E药经理人的镜头，回看一下过去一段时间以来，医药行业的“高光时刻”。又到了拼中秋福利的时候了，一起看看各大药企都发了啥？CDE又搬家了！搬家是大事，对CDE这样的部门来说，更是大事。药审改革至今8年了，加上这次，CDE共搬了2次家。CDE每一次搬家，可以说，背后都与药品监管理念的改变密切相关，这可关系着产业的发展和诸多药企的“命脉”。以5000亿美元市值登顶全球生物医药市值冠军，医药行业最当红的仔，非礼来莫属。营收甚至还没挤进全球前十的礼来，是怎么登上王座的？杨森改名了意味着什么？意味着在中国市场上，寄托了一批医药人心中纯真时代的那个名字成为了历史，从此世间再无“杨森”……阿斯利康要把中国业务单独拆分出来？还要在港交所上市？《金融时报》传言阿斯利康中国区即将分拆上市这事儿，离谱但又合理……本土企业，你慌了吗？当你老了，走不动了，炉火旁打盹，想不起你，也忆不起青春……你知道吗？现实中《当你老了》这首让人泪目歌的画风很可能是这样的！跳楼、逼宫、全员解散……7天的时间，产业里流传的各种公司与不公开信息，撕下了创新药企用之前多少年构建起来的体面……生存与毁灭，谁会“死”在周期里？遭受“死亡”威胁的biotech，如果100家里只能剩下5家，你觉得会有谁？回复“新生”，了解电子期刊详情登记邮箱信息订阅E药经理人信息服务扫描二维码精彩推荐CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化 ｜ 猎药人系列专题启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖 ｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 |  荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药 ｜再鼎医药｜亚虹医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元

Structure Therapeutics aims to enter phase 2b next year. Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks. But a mistake in a larger, longer clinical trial has pushed back data that will give a clearer picture of how its candidate holds up against rival oral obesity drugs in development at Eli Lilly, Novo Nordisk and Pfizer. San Francisco-based Structure rode rising interest in targeting GLP-1 to treat obesity to pull off a $185 million IPO earlier this year. The biotech’s lead candidate is an oral small molecule that it argues is easier to use than obesity and diabetes injectables such as Lilly’s Mounjaro and Novo’s Ozempic and has a wider safety window than oral candidates in development at a clutch of leading drugmakers.    Structure has begun to deliver clinical data on its candidate, GSBR-1290, reporting single ascending dose results in June and following up with another readout Friday. The latest look at the drug candidate comes from a phase 1b multiple ascending dose trial. In the study, 24 healthy overweight or obese individuals received one of three doses of GSBR-1290 or placebo. After four weeks of once-daily dosing, participants on the highest dose had a 4.9% reduction in weight compared to their counterparts on placebo. The reduction at the middle dose, 4.6%, was similar, but the difference versus placebo fell away to 1.1% at the lowest dose.  Structure’s study is small, and cross-trial comparisons are unreliable, but the result suggests GSBR-1290 is competitive. The candidate is more convenient than Pfizer’s danuglipron and Novo Nordisk’s oral semaglutide—which are given twice daily and on an empty stomach with a sip of water, respectively—and posted similar weight loss figures to Lilly’s orforglipron at four weeks.  On the safety front, the most common adverse events were classwide issues, nausea and vomiting, which affected more patients in the higher two dose arms than in the placebo group. Structure said it saw no “clinically meaningful changes in liver function tests.” Pfizer dropped one of its oral obesity candidates earlier this year in response to a liver safety signal, although it is continuing to advance another asset.  One problem for Structure is that its rivals are deeper in development. Novo already has phase 3 data on its contender, and Lilly and Pfizer have finished phase 2 studies of their assets. The presence of advanced rivals led AstraZeneca to cull its early-phase candidate, citing a lack of differentiation, but Structure sees a space for GSBR-1290.  The biotech, which was co-founded by, and works with, Schrödinger, had planned to share obesity data from a phase 2a trial that could support its differentiation argument by the end of the year. However, a clinical site failed to collect weight data for 24 of the 40 participants at the final, Week 12 visit, forcing Structure to enroll additional participants. As such, while the diabetes cohort will report out as planned, Structure delayed obesity data to the first half of next year. Structure also aims to enter phase 2b in 2024. As Structure gathers longer-term data on GSBR-1290, it should, based on the experience of its rivals, see patients lose more and more weight. Lilly reported a 12.4%, placebo-adjusted reduction in weight after 36 weeks, which could increase at later time points, but it expects the figure to fall short of the efficacy of injectables.  The forecast efficacy gap has raised doubts about whether people will prefer injectables, but Lilly sees an opportunity for orals, particularly in “middle-income markets in China” where price is a bigger factor.